Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials-Reference-Cited by-同舟云学术

Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials

Published:2016-01-13 Issue:321 Volume:8 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Berry-Kravis Elizabeth¹,Des Portes Vincent²³,Hagerman Randi⁴,Jacquemont Sébastien⁵⁶,Charles Perrine⁷,Visootsak Jeannie⁸,Brinkman Marc⁹,Rerat Karin¹⁰,Koumaras Barbara¹¹,Zhu Liansheng¹²,Barth Gottfried Maria¹³,Jaecklin Thomas¹⁴,Apostol George¹⁴,von Raison Florian¹⁴

Affiliation:

1. Departments of Pediatrics, Neurological Sciences, and Biochemistry, Rush University Medical Center, Chicago, IL 60612, USA.

2. National Reference Center for Fragile X and Other X-Linked Intellectual Disabilities, CIC 1407 INSERM, Hospices Civils de Lyon, Université de Lyon, 69002 Lyon, France.

3. CNRS UMR 5304 (Laboratoire sur le Langage, le Cerveau et la Cognition), 69500 Bron, France.

4. Medical Investigation of Neurodevelopmental Disorders Institute and Department of Pediatrics, UC Davis Medical Center, Sacramento, CA 95817, USA.

5. Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne, Switzerland.

6. CHU Sainte-Justine Research Centre, Montreal, Quebec H3T 1C5, Canada.

7. Département de Génétique et Cytogénétique, Unité Fonctionnelle de Génétique Médicale, Assistance Publique–Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, 75013 Paris, France.

8. Department of Human Genetics, Emory University School of Medicine, Atlanta, GA 30322, USA.

9. Novartis Pharma GmbH, 90429 Nürnberg, Germany.

10. Novartis Pharmaceuticals SAS, 92500 Rueil-Malmaison, France.

11. Neurodegeneration Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936–1080, USA.

12. Integrated Quantitative Science, Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936–1080, USA.

13. Department of Child and Adolescent Psychiatry, University Hospital of Tübingen, 72076 Tübingen, Baden-Württemberg, Germany.

14. Neuroscience Development, Novartis Pharma AG, CH-4056 Basel, Switzerland.

Abstract

In contrast to previous studies, targeting the mGluR pathway in fragile X syndrome patients did not improve behavior independent of FMR1 methylation.

Funder

Novartis Pharma AG

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference33 articles.

1. R. J. Hagerman P. J. Hagerman Eds. Fragile X Syndrome: Diagnosis Treatment and Research (The Johns Hopkins University Press Baltimore 2002).

2. Screening for fragile X syndrome: a literature review and modelling study

3. Autism spectrum disorders: The quest for genetic syndromes

4. Epidemiology of fragile X syndrome: A systematic review and meta-analysis

5. Exploring the Adult Life of Men and Women With Fragile X Syndrome: Results From a National Survey

Cited by 212 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The neuropathobiology of multiple sclerosis;Nature Reviews Neuroscience;2024-05-24

2. Challenges in developing therapies in fragile X syndrome: how the FXLEARN trial can guide research;Journal of Clinical Investigation;2024-03-01

3. EZH2 inhibition reactivates epigenetically silenced FMR1 and normalizes molecular and electrophysiological abnormalities in fragile X syndrome neurons;Frontiers in Neuroscience;2024-02-21

4. mGluR7 allosteric modulator AMN082 corrects protein synthesis and pathological phenotypes in FXS;EMBO Molecular Medicine;2024-02-19

5. Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence;Expert Opinion on Pharmacotherapy;2024-02-11